Frank Mathias appointed CEO of Oxford Biomedica

Sunday 27 November 2022
Oxford Biomedica Plc
Appointee name
Frank Mathias

United Kingdom

Frank Mathias is to join Oxford Biomedica Plc as chief executive in March 2023 to lead the company’s viral vector development and manufacturing business. He will join from Rentschler Biopharma SE, a Germany-based contract development and manufacturing organisation. Prior to Rentschler, Dr Mathias was CEO of Medigene AG, which is developing T cell based cancer therapies. He has also held senior positions at Amgen Inc, Laboratoires Servier, and Hoechst AG.

Oxford Biomedica announced the appointment on 22 November 2022.

 Copyright 2022 Evernow Publishing Ltd